• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

免疫检查点阻断在肾细胞癌中的应用。

Immune checkpoint blockade in renal cell carcinoma.

机构信息

Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

出版信息

J Surg Oncol. 2021 Mar;123(3):739-750. doi: 10.1002/jso.26339.

DOI:10.1002/jso.26339
PMID:33595892
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8364550/
Abstract

Immune checkpoint blockade (ICB) is the foundation of current first-line therapies in patients with metastatic renal cell carcinoma (mRCC) with the potential for eliciting long-lasting remissions. With the expanding arsenal of ICB-based therapies, biomarkers of response are urgently needed to guide optimal therapeutic selection. We review the data behind ICB therapy in RCC, emerging biomarkers of response, and the evolving role of surgery in patients with mRCC.

摘要

免疫检查点阻断 (ICB) 是转移性肾细胞癌 (mRCC) 患者目前一线治疗的基础，具有引发持久缓解的潜力。随着基于 ICB 的治疗方法不断增加，迫切需要反应生物标志物来指导最佳治疗选择。我们回顾了 RCC 中 ICB 治疗的相关数据、新的反应生物标志物以及手术在 mRCC 患者中的作用演变。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b6ca/8364550/77c5d51a8c09/nihms-1722163-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b6ca/8364550/77c5d51a8c09/nihms-1722163-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b6ca/8364550/77c5d51a8c09/nihms-1722163-f0001.jpg

相似文献

1
Immune checkpoint blockade in renal cell carcinoma.免疫检查点阻断在肾细胞癌中的应用。
J Surg Oncol. 2021 Mar;123(3):739-750. doi: 10.1002/jso.26339.
2
Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma.卡博替尼在转移性透明细胞肾细胞癌免疫检查点阻断后的活性。
Eur J Cancer. 2020 Aug;135:203-210. doi: 10.1016/j.ejca.2020.05.009. Epub 2020 Jun 27.
3
promoter hypomethylation is a negative prognostic biomarker at initial diagnosis but predicts response and favorable outcome to anti-PD-1 based immunotherapy in clear cell renal cell carcinoma.启动子低甲基化是初诊时的一个负预后生物标志物，但在透明细胞肾细胞癌中，它预测对基于抗 PD-1 的免疫治疗有反应和良好的结果。
J Immunother Cancer. 2021 Aug;9(8). doi: 10.1136/jitc-2021-002949.
4
Upfront Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors or Targeted Therapy: An Observational Study from the International Metastatic Renal Cell Carcinoma Database Consortium.免疫检查点抑制剂或靶向治疗的转移性肾细胞癌患者的 upfront 减瘤性肾切除术：来自国际转移性肾细胞癌数据库联盟的一项观察性研究
Eur Urol. 2023 Feb;83(2):145-151. doi: 10.1016/j.eururo.2022.10.004. Epub 2022 Oct 20.
5
Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients.肠道细菌组成驱动肾细胞癌患者对癌症免疫疗法的原发性耐药性。
Eur Urol. 2020 Aug;78(2):195-206. doi: 10.1016/j.eururo.2020.04.044. Epub 2020 May 4.
6
Biomarkers for evaluating the clinical response to immune checkpoint inhibitors in renal cell carcinoma (Review).评估免疫检查点抑制剂在肾细胞癌中的临床应答的生物标志物（综述）。
Oncol Rep. 2024 Dec;52(6). doi: 10.3892/or.2024.8823. Epub 2024 Oct 18.
7
Complete response and renal cell carcinoma in the immunotherapy era: The paradox of good news.免疫治疗时代的完全缓解和肾细胞癌：好消息中的矛盾。
Cancer Treat Rev. 2021 Sep;99:102239. doi: 10.1016/j.ctrv.2021.102239. Epub 2021 Jun 1.
8
Radical Nephrectomy After Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma.免疫检查点抑制剂治疗转移性肾细胞癌后的根治性肾切除术。
Eur Urol Focus. 2023 Mar;9(2):275-277. doi: 10.1016/j.euf.2023.01.022. Epub 2023 Feb 10.
9
Checkpoint inhibitors in metastatic papillary renal cell carcinoma.转移性乳头状肾细胞癌的检查点抑制剂。
Cancer Treat Rev. 2021 Sep;99:102228. doi: 10.1016/j.ctrv.2021.102228. Epub 2021 May 20.
10
Current status and future perspective of immunotherapy for renal cell carcinoma.肾细胞癌免疫治疗的现状与展望。
Int J Clin Oncol. 2024 Aug;29(8):1105-1114. doi: 10.1007/s10147-023-02446-3. Epub 2023 Dec 18.

引用本文的文献

1
Revisiting Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma: Real-World Evidence of Survival Benefit with First-Line Immunotherapy and Targeted Therapy Regimens.重新审视转移性肾细胞癌的减瘤性肾切除术：一线免疫治疗和靶向治疗方案生存获益的真实世界证据
J Clin Med. 2025 Aug 6;14(15):5543. doi: 10.3390/jcm14155543.
2
Gene expression of prostate-specific membrane antigen (FOLH1) in clear cell renal cell carcinoma predicts angiogenesis and response to tyrosine kinase inhibitors.前列腺特异性膜抗原（FOLH1）在透明细胞肾细胞癌中的基因表达可预测血管生成及对酪氨酸激酶抑制剂的反应。
Urol Oncol. 2025 Mar;43(3):192.e21-192.e28. doi: 10.1016/j.urolonc.2024.10.013. Epub 2024 Nov 12.
3

本文引用的文献

1
Multicenter randomized trial of deferred cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma receiving checkpoint inhibitors: the NORDIC-SUN-Trial.多中心随机对照试验：在接受检查点抑制剂治疗的同步转移性肾细胞癌中延迟细胞减灭性肾切除术：北欧-太阳试验。
BMC Cancer. 2024 Feb 24;24(1):260. doi: 10.1186/s12885-024-11987-3.
2
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.帕博利珠单抗治疗的晚期实体瘤患者肿瘤突变负荷与结局的相关性：多队列、开放标签、Ⅱ期 KEYNOTE-158 研究的前瞻性生物标志物分析。
Lancet Oncol. 2020 Oct;21(10):1353-1365. doi: 10.1016/S1470-2045(20)30445-9. Epub 2020 Sep 10.
3
2022 WUOF/SIU International Consultation on Urological Diseases: Genetics and Tumor Microenvironment of Renal Cell Carcinoma.
2022年世界泌尿外科联合会/国际泌尿外科协会肾细胞癌泌尿疾病国际咨询会：遗传学与肿瘤微环境
Soc Int Urol J. 2022 Nov;3(6):386-396. doi: 10.48083/BLPV3411.
4
VHL loss reprograms the immune landscape to promote an inflammatory myeloid microenvironment in renal tumorigenesis.VHL缺失重编程免疫格局，以促进肾肿瘤发生过程中的炎症性髓系微环境。
J Clin Invest. 2024 Apr 15;134(8):e173934. doi: 10.1172/JCI173934.
5
Analysis of the Tumor Immune Microenvironment (TIME) in Clear Cell Renal Cell Carcinoma (ccRCC) Reveals an M0 Macrophage-Enriched Subtype: An Exploration of Prognostic and Biological Characteristics of This Immune Phenotype.透明细胞肾细胞癌（ccRCC）肿瘤免疫微环境（TIME）分析揭示一种富含M0巨噬细胞的亚型：对这种免疫表型的预后和生物学特征的探索
Cancers (Basel). 2023 Nov 22;15(23):5530. doi: 10.3390/cancers15235530.
6
HAPLN3 inhibits apoptosis and promotes EMT of clear cell renal cell carcinoma via ERK and Bcl-2 signal pathways.HAPLN3 通过 ERK 和 Bcl-2 信号通路抑制透明细胞肾细胞癌的细胞凋亡并促进 EMT。
J Cancer Res Clin Oncol. 2023 Jan;149(1):79-90. doi: 10.1007/s00432-022-04421-3. Epub 2022 Nov 14.
7
Radiogenomics in Clear Cell Renal Cell Carcinoma: A Review of the Current Status and Future Directions.透明细胞肾细胞癌中的放射基因组学：现状与未来方向综述
Cancers (Basel). 2022 Apr 22;14(9):2085. doi: 10.3390/cancers14092085.
8
The Upregulation of Molecules Related to Tumor Immune Escape in Human Pituitary Adenomas.人类垂体腺瘤中与肿瘤免疫逃逸相关分子的上调。
Front Endocrinol (Lausanne). 2021 Oct 21;12:726448. doi: 10.3389/fendo.2021.726448. eCollection 2021.
9
Multidiscipline Immunotherapy-Based Rational Combinations for Robust and Durable Efficacy in Brain Metastases from Renal Cell Carcinoma.多学科免疫治疗为基础的合理组合在肾细胞癌脑转移中获得持久和稳健的疗效。
Int J Mol Sci. 2021 Jun 11;22(12):6290. doi: 10.3390/ijms22126290.
10
Neoadjuvant Nivolumab in Patients with High-risk Nonmetastatic Renal Cell Carcinoma.新辅助纳武利尤单抗治疗高危局限性肾细胞癌患者。
Eur Urol Oncol. 2022 Feb;5(1):113-117. doi: 10.1016/j.euo.2021.04.002. Epub 2021 May 26.
Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial.avelumab 联合阿昔替尼对比舒尼替尼用于晚期肾细胞癌：III 期 JAVELIN Renal 101 试验的生物标志物分析。
Nat Med. 2020 Nov;26(11):1733-1741. doi: 10.1038/s41591-020-1044-8. Epub 2020 Sep 7.
4
Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab Treatment in Patients with Advanced Renal Cell Carcinoma.阿昔替尼/帕博利珠单抗治疗晚期肾细胞癌患者的血管生成和免疫相关生物标志物及结局。
Clin Cancer Res. 2020 Nov 1;26(21):5598-5608. doi: 10.1158/1078-0432.CCR-20-1408. Epub 2020 Aug 18.
5
Immunomodulatory Roles of VEGF Pathway Inhibitors in Renal Cell Carcinoma.血管内皮生长因子通路抑制剂在肾细胞癌中的免疫调节作用。
Drugs. 2020 Aug;80(12):1169-1181. doi: 10.1007/s40265-020-01327-7.
6
DNA damage repair pathway alterations in metastatic clear cell renal cell carcinoma and implications on systemic therapy.转移性透明细胞肾细胞癌中 DNA 损伤修复途径的改变及其对系统治疗的影响。
J Immunother Cancer. 2020 Jun;8(1). doi: 10.1136/jitc-2019-000230.
7
Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma.体细胞改变与免疫浸润的相互作用调节晚期透明细胞肾细胞癌对 PD-1 阻断的反应。
Nat Med. 2020 Jun;26(6):909-918. doi: 10.1038/s41591-020-0839-y. Epub 2020 May 29.
8
Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients.肠道细菌组成驱动肾细胞癌患者对癌症免疫疗法的原发性耐药性。
Eur Urol. 2020 Aug;78(2):195-206. doi: 10.1016/j.eururo.2020.04.044. Epub 2020 May 4.
9
Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma.新诊断转移性肾细胞癌患者的延迟细胞减少性肾切除术。
Eur Urol. 2020 Oct;78(4):615-623. doi: 10.1016/j.eururo.2020.04.038. Epub 2020 Apr 30.
10
Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis.免疫相关不良反应与癌症患者免疫检查点抑制剂疗效的相关性：系统评价和荟萃分析。
BMC Med. 2020 Apr 20;18(1):87. doi: 10.1186/s12916-020-01549-2.